Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

This study has been completed.
Sponsor:
Collaborator:
Mclean Hospital
Information provided by (Responsible Party):
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000211
First received: September 20, 1999
Last updated: April 30, 2013
Last verified: December 2002
  Purpose

The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Heroin Dependence
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment Efficacy for Drug Abuse and AIDS Prevention

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   26 Years to 41 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000211

Locations
United States, Massachusetts
McLean Hospital, Dept. of Psychiatry
Belmont, Massachusetts, United States, 2178
Sponsors and Collaborators
Mclean Hospital
Investigators
Principal Investigator: Jack Mendelson, M.D. Mclean Hospital
  More Information

No publications provided

Responsible Party: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000211     History of Changes
Other Study ID Numbers: NIDA-06116-2, R18-06116-2
Study First Received: September 20, 1999
Last Updated: April 30, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Heroin Dependence
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Opioid-Related Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Narcotic Antagonists

ClinicalTrials.gov processed this record on September 16, 2014